About ObsEva
ObsEva is a publicly listed company based in Geneve (Switzerland) founded in 2012. It operates as a therapeutics for womens reproductive health and pregnancy are developed. ObsEva has raised $94.7 million across 6 funding rounds from investors including Merck, New Leaf Venture Partners and Orbimed. Its focus areas include Life Sciences, Women Health, Drugs and Reproductive Diseases. Its legal entity is OBSEVA SA. Its competitors include Sprout Pharmaceuticals, Hope Medicine, Rejoni, Gameto and Forendo Pharma and 3 more; 8 of its 8 listed competitors have raised funding.
Company details
Developer of therapeutics for womens reproductive health and pregnancy. Its lead candidate is Linzagolix an orally active gonadotropin-releasing hormone and receptor antagonist for Fibroids and Endometriosis. It also has two receptor antagonists Ebopiprant and Nolasiban for preterm labor.
- Headquarters Geneve, Switzerland
- Stage Public
- SectorsHealthcare
- Website obseva.com
- Social LinkedIn
- Legal Name Obseva Sa
- Annual Revenue$19.64 M (USD)-12as on Dec 31, 2022
- Net Profit-$29.88 M (USD)44as on Dec 31, 2022
- EBITDA-$15.68 M (USD)72as on Dec 31, 2022
- Total Equity Funding$94.7M (USD)
in 6 rounds
- InvestorsMerck
& 15 more
Funding Insights of ObsEva
ObsEva has successfully raised a total of $94.7M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $94.7M
- Total Rounds 6
- First Round $34.7M
(Aug 2013)
- Investors Count 16
All 6 funding rounds of ObsEva with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | – | Post-IPO | – | – | – |
| Aug 2019 | $75M | Debt – Conventional | – | – | |
| Oct 2017 | $60M | Post-IPO | – | – | |
| Aug 2017 | – | Post-IPO | – | – | |
| Nov 2015 | $60M | Series B | – | HBM Healthcare Investments, New Enterprise Associates | – |
| Aug 2013 | $34.7M | Series A | – | Sofinnova Partners |
16 investors in total: 16 institutional.
Investors in ObsEva
ObsEva has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, New Leaf Venture Partners and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Venture capital investments are offered to startups by NEA. | – | nea.com | Menlo Park, United States | |
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Venture capital firm focused on tech sectors | – | venrock.com | Palo Alto, United States | |
PE firm investing in the US | – | aislingcapital.com | New York, United States | |
Venture capital firm | – | omegafunds.com | Boston, United States | |
Sofinnova Partners is focused on life sciences and healthcare investments. | – | sofinnovapartners.com | Paris, France | |
Early-stage life science focused VC firm investing in geographies such as Europe and the US | – | medicxi.com | London, United Kingdom | |
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States |
Investor details for ObsEva
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ObsEva
5 people are tracked at ObsEva (2 in leadership, 1 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Jean-Pierre Gotteland | Chief Scientific Officer & Head of R&D | Leadership |
Bandu Cristina | PV Director | Leadership |
Catarina Edfjäll | Director | Board & advisors |
Sébastien Charpentier | Clinical Operations Manager | Team |
Luigi Marro | Board Member & Executive Consultant | Team |
Complete people profiles for ObsEva
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ObsEva
4 dated milestones of ObsEva across 11 years, from founding to its latest funding, stage changes and deals.
- Founded ObsEva is founded.
- Funding First funding round of $34.7M.
- Funding Latest funding round, Post-IPO,.
- IPO Lists on the stock exchange (IPO).
Competitors of ObsEva
ObsEva has 8 listed competitors in our database, 8 of them funded. They include Sprout Pharmaceuticals, Hope Medicine, Rejoni, Gameto and Forendo Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sproutpharmaceuticals.com | 2011 | Raleigh, United States | $185.16M | 31 | Drugs for hypoactive sexual desire disorder in women are developed. | |
| hopemedinc.com | 2018 | Shanghai, China | $56M | – | Monoclonal antibodies are developed for treating multiple diseases. | |
| rejoni.com | 2020 | Bedford, United States | $41.25M | – | Therapeutics for women's health conditions are developed using innovative hydrogels. | |
| gametogen.com | 2020 | United States | $127M | – | Therapeutics for fertility and menopause treatments are developed. | |
| forendo.com | 2013 | Turku, Finland | $25.58M | – | Small molecule therapeutics for reproductive health are developed. | |
| noratherapeutics.com | 2007 | Palo Alto, United States | $37.81M | – | Therapeutics for IVF failure and recurrent pregnancy loss are developed. | |
| naari.co | 2007 | Noida, India | $18.98M | 195 | Women care medicines are manufactured by Naari in India. | |
| preglem.com | 2006 | Geneva, Switzerland | $57.94M | – | Innovative drugs for women's reproductive medicine are developed and commercialized. |
Detailed competitors of ObsEva
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ObsEva
Websites that share an audience with ObsEva (obseva.com).
Websites whose visitors overlap most with ObsEva. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
compliance-instituut.nl | compliance-instituut.nl | 100% | – | #7,139,738 | – |
Top companies in Women's Health & Fertility
10 companies that operate in the same segment as ObsEva (Women's Health & Fertility), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Internet first brand offering wearable breast pumps | 2013 | London, England, United Kingdom | USD 157.63 M | – | – | |
Silicone-filled breast and body shaping implants are designed and manufactured. | 2010 | Alajuela, Alajuela, Costa Rica | USD 121 M | USD 211.08 M | 1,020 | |
Immunotherapeutics for cancer and other diseases are developed. | 2008 | Mainz, Rhineland-palatinate, Germany | USD 805.99 M | USD 3.24 B | 6,770 | |
Developer of cell-free DNA testing for oncology, women’s health, and organ health | 2004 | Redwood City, California, United States | USD 152.1 M | USD 2.31 B | 4,430 | |
Therapeutics for women's healthcare are developed and offered. | 1997 | Princeton, New Jersey, United States | USD 123.06 M | USD 19.59 M | – | |
Provider of cell-free cancer liquid biopsy test | 2015 | San Francisco, California, United States | USD 388.62 M | – | 861 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Platform for breast ultrasound imaging | 2010 | Plymouth, Massachusetts, United States | USD 136.54 M | – | – | |
Silicone breast implants are developed for reconstruction and aesthetic surgery. | 2007 | Dublin, Ireland | USD 232.81 M | – | – | |
A minimally invasive ablation system for uterine fibroids is developed. | 2005 | Redwood City, California, United States | USD 282.54 M | – | 92 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Obseva
Complete news archive for ObsEva
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ObsEva
ObsEva was founded in 2012 and raised its 1st funding round 1 year after it was founded.
ObsEva is headquartered in Geneve, Switzerland. It is registered at Geneve, Geneve, Switzerland.
ObsEva is a funded company, having raised a total of $94.7M across 6 funding rounds to date. The company's 1st funding round was a Series A of $34.7M, raised on Aug 2013.
Annual revenue of ObsEva is $19.64M as on Dec 31, 2022.
Developer of therapeutics for womens reproductive health and pregnancy. Its lead candidate is Linzagolix an orally active gonadotropin-releasing hormone and receptor antagonist for Fibroids and Endometriosis. It also has two receptor antagonists Ebopiprant and Nolasiban for preterm labor.
ObsEva's top competitors include Sprout Pharmaceuticals, Rejoni and Hope Medicine.
ObsEva has 16 investors. Key investors include Merck, New Leaf Venture Partners, Orbimed, Oxford Finance, and HBM Healthcare Investments.
ObsEva operates through Obseva Sa.